Integra LifeSciences (IART) Tops Q2 EPS by 14c

Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.71, $0.14 better than the analyst estimate of $0.57. Revenue for the quarter came in at $381.3 million versus the consensus estimate of $374.07 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Integra LifeSciences Announces Key Executive Appointments
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'